Vigil Neuroscience (VIGL) Competitors

Outlook Therapeutics (NASDAQ:OTLK) and Vigil Neuroscience (NASDAQ:VIGL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Do institutionals and insiders believe in OTLK or VIGL?

11.2% of Outlook Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Vigil Neuroscience shares are owned by institutional investors. 5.3% of Outlook Therapeutics shares are owned by insiders. Comparatively, 33.5% of Vigil Neuroscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer OTLK or VIGL?

Outlook Therapeutics received 138 more outperform votes than Vigil Neuroscience when rated by MarketBeat users. However, 72.73% of users gave Vigil Neuroscience an outperform vote while only 70.32% of users gave Outlook Therapeutics an outperform vote.

Company	Underperform	Outperform
Outlook Therapeutics	Outperform Votes 154 70.32%	Underperform Votes 65 29.68%
Vigil Neuroscience	Outperform Votes 16 72.73%	Underperform Votes 6 27.27%

Does the media prefer OTLK or VIGL?

In the previous week, Outlook Therapeutics had 4 more articles in the media than Vigil Neuroscience. MarketBeat recorded 8 mentions for Outlook Therapeutics and 4 mentions for Vigil Neuroscience. Outlook Therapeutics' average media sentiment score of 0.85 beat Vigil Neuroscience's score of 0.22 indicating that Vigil Neuroscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Outlook Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vigil Neuroscience	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk & volatility, OTLK or VIGL?

Outlook Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.

Do analysts prefer OTLK or VIGL?

Outlook Therapeutics presently has a consensus target price of $46.43, suggesting a potential upside of 478.14%. Vigil Neuroscience has a consensus target price of $17.40, suggesting a potential upside of 528.16%. Given Outlook Therapeutics' higher possible upside, analysts clearly believe Vigil Neuroscience is more favorable than Outlook Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Outlook Therapeutics	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Vigil Neuroscience	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is OTLK or VIGL more profitable?

Outlook Therapeutics' return on equity of -57.26% beat Vigil Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Outlook Therapeutics	N/A	-3,741.39%	-132.37%
Vigil Neuroscience	N/A	-57.26%	-49.50%

Which has better valuation & earnings, OTLK or VIGL?

Outlook Therapeutics is trading at a lower price-to-earnings ratio than Vigil Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Outlook Therapeutics	N/A	N/A	-$58.98M	-$4.00	-2.05
Vigil Neuroscience	N/A	N/A	-$82.64M	-$2.13	-1.30

Summary

Vigil Neuroscience beats Outlook Therapeutics on 10 of the 15 factors compared between the two stocks.